In our previous single dose two-period cross-over 
bioequivalence study for gefitinib generic products in dogs under fasting 
condition, the results also did not match the acceptance criteria.Anal ysis of variance (ANOVA) revealed that there were significant differ ences between two periods and between individuals.A single-oral-dose, two-period, 
cross-over bioequivalence study was carried out in 12 Beagle dogs, with 
a washout interval of 7 days, approximately 24 half-lives (Mckillop 
et al., 2004).